<DOC>
	<DOCNO>NCT03088605</DOCNO>
	<brief_summary>In subject Dry Eye Syndrome : The primary objective study compare safety tolerability TOP1630 Ophthalmic Solution placebo . The secondary objective compare efficacy TOP1630 Ophthalmic Solution placebo treatment sign symptom dry eye syndrome .</brief_summary>
	<brief_title>Safety Efficacy TOP1630 Dry Eye Syndrome</brief_title>
	<detailed_description>This study design assess safety , tolerability efficacy TOP1630 ophthalmic solution subject Dry Eye Syndrome . Eligible subject randomize double mask either TOP1630 placebo . Part 1 ( time frame 12 day ) comprise assessment safety , tolerability ocular comfort . Part 2 ( time frame 35 day ) comprise assessment safety , tolerability efficacy</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Be least 18 year age ; Provide write informed consent ; Have report history dry eye ; Have history use eye drop dry eye symptom ; Additionally Part 2 Symptoms dry eye syndrome include : Ocular discomfort Conjunctival redness Tear film break time Schirmer test score Signs dry eye syndrome include : Conjunctival stain score Have clinically significant slit lamp finding entry visit ; Be diagnose ongoing ocular infection ; Have significant ocular lesion could interfere assessment safety efficacy prevent study conduct opinion PI ; Have plan ocular and/or lid surgery study period ; Have uncontrolled systemic disease ; Be woman pregnant , nurse planning pregnancy ; Be woman childbearing potential use acceptable mean birth control ; Have know allergy and/or sensitivity test article component ; Have condition situation investigator feel may put subject significant risk , may confound study result , may interfere significantly subject 's participation study ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>